Mine Y, Yokota Y, Wakai Y, Fukada S, Nishida M, Goto S, Kuwahara S
J Antibiot (Tokyo). 1983 Aug;36(8):1045-50. doi: 10.7164/antibiotics.36.1045.
The protective effect of an immunoactive peptide, D-lactoyl-L-alanyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(L)-glycine (FK-156) and a related compound, heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine (FK-565) was determined in mice with various kinds of microbial infections. FK-156 and FK-565 were given to mice either subcutaneously or orally before challenge. The drugs enhanced significantly the defense of mice against acute systemic infections induced by various extracellular and facultative intracellular organisms, and subcutaneous abscess by Staphylococcus aureus. The protective effect of these drugs against Escherichia coli infection differed considerably depending on the route of administration; FK-156 was only effective by the parenteral route; however, FK-565 was effective by both parenteral and oral routes. After subcutaneous dosing with FK-156, the enhancement of host defense of mice against E. coli infection was more rapid than against Listeria infection. The enhancing effects of FK-156 and FK-565 on host defense of mice against pseudomonal infection was more potent than other immunoactive drugs.
在患有各种微生物感染的小鼠中测定了免疫活性肽D-乳酰-L-丙氨酰-γ-D-谷氨酰-(L)-内消旋二氨基庚二酸-(L)-甘氨酸(FK-156)和相关化合物庚酰-γ-D-谷氨酰-(L)-内消旋二氨基庚二酸-(D)-丙氨酸(FK-565)的保护作用。在攻毒前,将FK-156和FK-565皮下或口服给予小鼠。这些药物显著增强了小鼠对由各种细胞外和兼性细胞内生物体引起的急性全身感染以及金黄色葡萄球菌引起的皮下脓肿的防御能力。这些药物对大肠杆菌感染的保护作用因给药途径的不同而有很大差异;FK-156仅通过肠胃外途径有效;然而,FK-565通过肠胃外和口服途径均有效。皮下给予FK-156后,小鼠对大肠杆菌感染的宿主防御增强比针对李斯特菌感染的增强更快。FK-156和FK-565对小鼠抗铜绿假单胞菌感染的宿主防御增强作用比其他免疫活性药物更强。